Cancer Research Annual Meeting 2010  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, L.
Right arrow Articles by Kufe, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, L.
Right arrow Articles by Kufe, D.
[Cancer Research 65, 10413-10422, November 15, 2005]
© 2005 American Association for Cancer Research


Cell and Tumor Biology

MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3ß–Mediated Phosphorylation and Degradation of ß-Catenin

Lei Huang, Dongshu Chen, Derek Liu, Li Yin, Surender Kharbanda and Donald Kufe

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Donald Kufe, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 617-632-3141; Fax: 617-632-2934; E-mail: donald_kufe{at}dfci.harvard.edu.

Dysregulation of ß-catenin is of importance to the development of diverse human malignancies. The MUC1 oncoprotein is aberrantly overexpressed by most human carcinomas and associates with ß-catenin. However, the functional significance of the MUC1-ß-catenin interaction is not known. Here, we show that MUC1 increases ß-catenin levels in the cytoplasm and nucleus of carcinoma cells. Previous studies have shown that glycogen synthase kinase 3ß (GSK3ß) phosphorylates ß-catenin and thereby targets it for proteosomal degradation. Consistent with the up-regulation of ß-catenin levels, our results show that MUC1 blocks GSK3ß-mediated phosphorylation and degradation of ß-catenin. To further define the interaction between MUC1 and ß-catenin, we identified a serine-rich motif (SRM) in the MUC1 cytoplasmic domain that binds directly to ß-catenin Armadillo repeats. Mutation of the SRM attenuated binding of MUC1 to ß-catenin and MUC1-mediated inhibition of ß-catenin degradation. Importantly, disruption of the MUC1-ß-catenin interaction with the SRM mutant also attenuated MUC1-induced anchorage-dependent and -independent growth and delayed MUC1-mediated tumorigenicity. These findings indicate that MUC1 promotes transformation, at least in part, by blocking GSK3ß-mediated phosphorylation and thereby degradation of ß-catenin.




This article has been cited by other articles:


Home page
DMMHome page
R. A. Budiu, I. Diaconu, R. Chrissluis, A. Dricu, R. P. Edwards, and A. M. Vlad
A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells
Dis. Model. Mech., November 1, 2009; 2(11-12): 593 - 603.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
MUC1 oncoprotein is a druggable target in human prostate cancer cells
Mol. Cancer Ther., November 1, 2009; 8(11): 3056 - 3065.



Home page
Cancer Res.Home page
R. Ahmad, D. Raina, M. D. Joshi, T. Kawano, J. Ren, S. Kharbanda, and D. Kufe
MUC1-C Oncoprotein Functions as a Direct Activator of the Nuclear Factor-{kappa}B p65 Transcription Factor
Cancer Res., September 1, 2009; 69(17): 7013 - 7021.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Raina, R. Ahmad, M. D. Joshi, L. Yin, Z. Wu, T. Kawano, B. Vasir, D. Avigan, S. Kharbanda, and D. Kufe
Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
Cancer Res., June 15, 2009; 69(12): 5133 - 5141.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. W. Poh, J. M. Bradley, P. Mukherjee, and S. J. Gendler
Lack of Muc1-Regulated {beta}-Catenin Stability Results in Aberrant Expansion of CD11b+Gr1+ Myeloid-Derived Suppressor Cells from the Bone Marrow
Cancer Res., April 15, 2009; 69(8): 3554 - 3562.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. P. Pitroda, N. N. Khodarev, M. A. Beckett, D. W. Kufe, and R. R. Weichselbaum
From the Cover: MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment
PNAS, April 7, 2009; 106(14): 5837 - 5841.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. N. Khodarev, S. P. Pitroda, M. A. Beckett, D. M. MacDermed, L. Huang, D. W. Kufe, and R. R. Weichselbaum
MUC1-Induced Transcriptional Programs Associated with Tumorigenesis Predict Outcome in Breast and Lung Cancer
Cancer Res., April 1, 2009; 69(7): 2833 - 2837.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Agata, R. Ahmad, T. Kawano, D. Raina, S. Kharbanda, and D. Kufe
MUC1 Oncoprotein Blocks Death Receptor-Mediated Apoptosis by Inhibiting Recruitment of Caspase-8
Cancer Res., August 1, 2008; 68(15): 6136 - 6144.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Kawano, M. Ito, D. Raina, Z. Wu, J. Rosenblatt, D. Avigan, R. Stone, and D. Kufe
MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
Cancer Res., December 15, 2007; 67(24): 11576 - 11584.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Sangha and C. Butts
L-BLP25: A Peptide Vaccine Strategy in Non Small Cell Lung Cancer
Clin. Cancer Res., August 1, 2007; 13(15): 4652s - 4654s.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. L. Beatty, S. E. Plevy, A. R. Sepulveda, and O. J. Finn
Cutting Edge: Transgenic Expression of Human MUC1 in IL-10-/- Mice Accelerates Inflammatory Bowel Disease and Progression to Colon Cancer
J. Immunol., July 15, 2007; 179(2): 735 - 739.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Leng, C. Cao, J. Ren, L. Huang, D. Chen, M. Ito, and D. Kufe
Nuclear Import of the MUC1-C Oncoprotein Is Mediated by Nucleoporin Nup62
J. Biol. Chem., July 6, 2007; 282(27): 19321 - 19330.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Wei, H. Xu, and D. Kufe
Human Mucin 1 Oncoprotein Represses Transcription of the p53 Tumor Suppressor Gene
Cancer Res., February 15, 2007; 67(4): 1853 - 1858.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Yin, S. Kharbanda, and D. Kufe
Mucin 1 Oncoprotein Blocks Hypoxia-inducible Factor 1{alpha} Activation in a Survival Response to Hypoxia
J. Biol. Chem., January 5, 2007; 282(1): 257 - 266.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
J. Ren, D. Raina, W. Chen, G. Li, L. Huang, and D. Kufe
MUC1 Oncoprotein Functions in Activation of Fibroblast Growth Factor Receptor Signaling
Mol. Cancer Res., November 1, 2006; 4(11): 873 - 883.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.